Prolonged inflammation following critical illness may impair long-term survival: A hypothesis with potential therapeutic implications

Medical Hypotheses

Volumn 75, Issue 1, 2010, Pages 32-34

  Grander, Wilhelm ^a   Dünser, Martin W ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CRITICALLY ILL PATIENT; DEATH; DISEASE DURATION; DNA POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTENSIVE CARE UNIT; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME;

CRITICAL ILLNESS; HUMANS; INFLAMMATION; PATIENT DISCHARGE; SURVIVAL RATE;

EID: 77953362101     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.01.020     Document Type: Article

References (47)

1. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resuscitation 2007, 9:8-18. ARISE; ANZICS APD Management Committee.
2. Erickson S.E., Martin G.S., Davis J.L., Matthay M.A. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009, 37:1574-1579. Eisner MD; NIH NHLBI ARDS Network.
3. Ho K.M., Knuiman M., Finn J., et al. Estimating long-term survival of critically ill patients: The PREDICT model. PloS One 2008, 3:3226.
4. Cheung A.M., Tansey C.M., Tomlinson G., et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006, 174:538-544.
5. Sasse K.C., Nauenberg E., Long A., Anton B., Tucker H.J., Hu T.W. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995, 23:1040-1047.
6. Williams T.A., Dobb G.J., Finn J.C., et al. Determinants of long-term survival after intensive care. Crit Care Med 2008, 36:1523-1530.
7. Niskanen M., Kari A., Halonen P. Five-year survival after intensive care - comparison of 12,180 patients with the general population. Finnish ICU Study Group. Crit Care Med 1996, 24:1962-1967.
8. Heyland D.K., Hopman W., Coo H., Tranmer J., McColl M.A. Long-term health-related quality of life in survivors of sepsis. Short form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28:3599-3605.
9. Schiffl Helmut, Fischer Rainald Five-year outcomes of severe acute kidney injury requiring renal replacement therapy. Nephrol Dial Transplant 2008, 23:2235-2241.
10. Maier R.V. Pathogenesis of multiple organ dysfunction syndrome - endotoxin, inflammatory cells, and their mediators: cytokines and reactive oxygen species. Surg Infect (Larchmt) 2000, 1:197-205.
11. Osuchowski M.F., Welch K., Siddiqui J., Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006, 177:1967-1974.
12. Vollmer-Conna U., Piraino B.F., Cameron B., et al. Cytokine polymorphisms have a synergistic effect on severity of the acute sickness response to infection. Clin Infect Dis 2008, 47:1418-1425.
13. Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992, 215:356-362.
14. Riché F.C., Cholley B.P., Panis Y.H., et al. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000, 28:433-437.
15. Meduri G.U., Headley S., Kohler G., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995, 107:1062-1073.
16. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37:291-304.
17. Póvoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002, 28:235-243.
18. Ho K.M., Dobb G.J., Lee K.Y., Towler S.C., Webb S.A. C-reactive protein concentration as a predictor of intensive care unit readmission: a nested case-control study. J Crit Care 2006, 21:259-265.
19. Ho K.M., Lee K.Y., Dobb G.J., Webb S.A. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. Intensive Care Med 2008, 34:481-487.
20. Litton E., Ho K.M., Chamberlain J., Dobb G.J., Webb S.A. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a nested case-control study. Crit Care Resuscitation 2007, 9:19-25.
21. Grander W., Dünser M.W., Dengg C., Koller B., Eller P., Tilg H. Acute inflammation and long-term mortality in non-surgical intensive care patients. Intensive Care Med 2009, 35(Suppl. 1):A320.
22. Yende S., D'Angelo G., Kellum J.A., et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177:1242-1247.
23. Lawrence T, Fong C. The Resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 2009;December 18 [Epub ahead of print].
24. Winsauer G., de Martin R. Resolution of inflammation: intracellular feedback loops in the endothelium. Thromb Haemost 2007, 97:364-369.
25. Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther 2006, 2:111-119.
26. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138. Leducq Transatlantic Network on Atherothrombosis.
27. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65(12 Pt 2):S253-S259.
28. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
29. Galarraga B., Khan F., Kumar P., Pullar T., Belch J.J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1780-1784.
30. Hasuike Y., Nonoguchi H., Ito K., et al. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 2009, 30:389-398.
31. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97(2A):3A-11A.
32. Beeh K.M., Glaab T. Is there a role for antiinflammatory treatment in COPD?. COPD 2009, 6:395-403.
33. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
34. Erlinger T.P., Platz E.A., Rifai N., Helzlsouer K.J. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-590.
35. Siemes C., Visser L.E., Coebergh J.W., et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006, 24:5216-5222.
36. Mayr V.D., Dünser M.W., Greil V., et al. Crit Care 2006, 10:R154.
37. Ridley S., Purdie J. Cause of death after critical illness. Anaesthesia 1992, 47:116-119.
38. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006, 260:305-319.
39. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
40. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;(2):. ncbi-n:CD007784.
41. Mortensen E.M., Copeland L.A., Pugh M.J., et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009, 10:45.
42. Kertai M.D., Boersma E., Westerhout C.M., et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004, 116:96-103.
43. Kulik A., Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. Expert Opin Drug Saf 2009, 8:559-571.
44. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
45. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
46. Glynn R.J., Danielson E., Fonseca F.A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009, 360:1851-1861.
47. Everett BM, Glynn RJ, Macfadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein. Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation 2009;December 21 [Epub ahead of print].